New Under-Eye Growth Factor Treatment Enters FDA Trial
A new injectable treatment is entering clinical trials to test if it can naturally regenerate tissue under the eyes.
Updated on Oct. 31, 2026 in Beauty
Live Poll
Do you believe new cosmetic injectable treatments require more extensive long-term safety testing before public availability?
Lynch Regenerative Medicine has received FDA authorization to begin Phase 2b clinical trials for an injectable growth factor treatment. The therapy aims to address infraorbital hollowing, a condition involving skin thinning and tissue loss under the eyes.
Why it matters
This development represents a shift toward regenerative approaches for under-eye hollowing, which currently relies on traditional fillers or surgical procedures. The study aims to determine if tissue regeneration can offer a more natural, gradual improvement in appearance.
The clinical trial is a multi-center, randomized, dose-ranging study evaluating safety and efficacy at 12 weeks. Researchers are measuring outcomes based on the Canfield Infraorbital Hollowing Scale, though the treatment is currently experimental and not approved for use.
The players
Lynch Regenerative Medicine
A biotechnology developer focused on tissue regeneration and growth factor therapeutics.
FDA
The United States federal agency responsible for regulating medical products and authorizing clinical trial pathways.
The details
The treatment uses recombinant human platelet-derived growth factor-BB to stimulate gradual tissue growth under the skin. Unlike standard dermal fillers that provide immediate volume, this injectable approach seeks to encourage the body to regenerate its own supporting tissue. The Phase 2b study will assess the safety, efficacy, durability, and immunogenicity of this regenerative method.
Timeline
12 weeks: Duration for primary safety and efficacy benchmark assessment.
Health Landscape
This study sits within the evolving field of cosmetic regenerative medicine, which seeks to move beyond temporary filling agents. It follows a broader trend of utilizing growth factors to address structural tissue loss through biological stimulation rather than mechanical volume replacement.
Because this treatment is currently in experimental clinical trials, it is not available for purchase or clinical use. If you are exploring treatments for under-eye concerns, consult a board-certified dermatologist to discuss established, FDA-approved options and their associated risks.
The takeaway
Regenerative medicine may eventually offer a way to treat under-eye hollowing by stimulating natural tissue growth rather than using synthetic fillers. For now, track advancements in clinical research and consult your physician regarding the safety of current cosmetic procedures.
Further reading
Learn more about the latest innovations in Beauty and how they are changing non-invasive treatment options.
Source note: This article includes information reported by Personalcareinsights.
Live Poll
Do you believe new cosmetic injectable treatments require more extensive long-term safety testing before public availability?
